REG-Bioventix Plc: Notice of Results

BioventixAnnouncement

11/09/2019 09:45

Bioventix plc
(“Bioventix” or “the Company”)

Notice of Results and Notice of AGM

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that it will release its preliminary results
for the year ended 30 June 2019 on 21 October 2019.

The Company’s Annual General Meeting will be held on Thursday 12 December at
2.00 p.m. at Farnham Castle, Castle Street, Farnham, Surrey, GU9 0AG.

For further information please contact:

 Bioventix plc Peter Harrison                   Chief Executive Officer  Tel: 01252 728 001  
                                                                                             
 finnCap Ltd Geoff Nash/Simon Hicks Alice Lane  Corporate Finance ECM    Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2019 PR Newswire Association,LLC. All Rights Reserved